Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review. 2015

Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
Department of Biological Sciences, Indian Institute of Science Education & Research Bhopal (IISER Bhopal), I.T.I. Transit Campus, Govindpura, Bhopal, 462023, M.P., India. prabhats@iiserb.ac.in.

Cancer is characterized by the uncontrolled division of cells, followed by their invasion to other tissues. These kinds of cellular abnormalities arise as a result of the accumulation of genetic mutations or epigenetic alterations. Targeting genetic mutations by drugs is a conventional treatment approach. Nowadays, the development and use of epigenetic drugs are burgeoning, owing to the advancements in epigenetic research. The therapeutic intervention of cancer development by histone deacetylase inhibitors (HDACIs) holds promise for helping to control the disease, but their nonspecific functions impose certain side effects. Therefore, the search for more HDACIs becomes essential. Plentiful literature on the versatility of dietary components including flavones, a class of the flavonoid group, has already established these compounds to be better anticancer agents. The present review focuses on the significance of flavones with regard to their HDACI-mimicking effects as suggested by the recent evidences. The review also proposes an in-depth screening of flavones in future studies, in the hope that flavones may provide a better alternative to synthetic HDACIs.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D044127 Epigenesis, Genetic A genetic process by which the adult organism is realized via mechanisms that lead to the restriction in the possible fates of cells, eventually leading to their differentiated state. Mechanisms involved cause heritable changes to cells without changes to DNA sequence such as DNA METHYLATION; HISTONE modification; DNA REPLICATION TIMING; NUCLEOSOME positioning; and heterochromatization which result in selective gene expression or repression. Epigenetic Processes,Epigenetic Process,Epigenetics Processes,Genetic Epigenesis,Process, Epigenetic,Processes, Epigenetic,Processes, Epigenetics
D047309 Flavones A group of 4-keto-FLAVONOIDS. 2-Phenyl-2-Ene-Benzopyran-4-One Compounds
D056572 Histone Deacetylase Inhibitors Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. HDAC Inhibitor,HDAC Inhibitors,Histone Deacetylase Inhibitor,Deacetylase Inhibitor, Histone,Deacetylase Inhibitors, Histone,Inhibitor, HDAC,Inhibitor, Histone Deacetylase,Inhibitors, HDAC,Inhibitors, Histone Deacetylase

Related Publications

Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
January 2009, The international journal of biochemistry & cell biology,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
July 2012, Antimicrobial agents and chemotherapy,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
September 2020, Advances in clinical and experimental medicine : official organ Wroclaw Medical University,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
July 2007, Biological psychiatry,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
January 2012, Evidence-based complementary and alternative medicine : eCAM,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
February 2006, Oncology reports,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
November 2012, European journal of cancer (Oxford, England : 1990),
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
April 2020, European journal of medicinal chemistry,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
December 2003, Current medicinal chemistry,
Prabhat Singh, and Raghuvir Singh Tomar, and Srikanta Kumar Rath
August 2019, Phytotherapy research : PTR,
Copied contents to your clipboard!